AKTS
Income statement / Annual
Last year (2024), Aktis Oncology, Inc.'s total revenue was $1.49 M,
and the percentage change from the previous year is not available.
In 2024, Aktis Oncology, Inc.'s net income was -$43.98 M.
See Aktis Oncology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$1.49 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$1.49 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
0
|
0
|
| Research and Development Expenses |
$40.95 M
|
$25.92 M
|
$14.30 M
|
| General & Administrative Expenses |
$11.31 M
|
$7.68 M
|
$5.11 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.31 M
|
$7.68 M
|
$5.11 M
|
| Other Expenses |
$1.28 M
|
$1.20 M
|
$356.00 K
|
| Operating Expenses |
$53.54 M
|
$34.79 M
|
$19.76 M
|
| Cost And Expenses |
$53.54 M
|
$34.79 M
|
$19.76 M
|
| Interest Income |
$8.10 M
|
$5.38 M
|
$1.65 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.58 M
|
$1.20 M
|
$445.00 K
|
| EBITDA |
-$50.48 M |
-$33.60 M |
-$19.32 M |
| EBITDA Ratio |
-33.94
|
0
|
0
|
| Operating Income Ratio |
-35
|
0
|
0
|
| Total Other Income/Expenses Net |
$8.07 M
|
$6.15 M
|
$1.84 M
|
| Income Before Tax |
-$43.98 M
|
-$28.64 M
|
-$17.93 M
|
| Income Before Tax Ratio |
-29.58
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$43.98 M
|
-$28.64 M
|
-$17.93 M
|
| Net Income Ratio |
-29.58
|
0
|
0
|
| EPS |
0 |
0 |
0 |
| EPS Diluted |
0 |
0 |
0 |
| Weighted Average Shares Out |
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
